Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.58 |
| ▸ | HTR1A | P08908 | 5/20 | 0.58 |
| ▸ | DRD3 | P35462 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.58 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
| ▸ | DRD5 | P21918 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7656340 | 0.96 | CYP2D6 (0.59) | DRD2HTR1ADRD3HTR2ADRD1 | |
| SCHEMBL26108581 | 0.89 | HTR1A (0.65) | DRD2HTR1ADRD3HTR2ADRD1 | |
| SCHEMBL26492991 | 0.89 | HTR1A (0.65) | DRD2HTR1ADRD3HTR2ADRD1 | |
| SCHEMBL15383634 | 0.89 | DRD2 (0.48) | DRD2HTR1ADRD3HTR2ADRD1 | |
| SCHEMBL1307809 | 0.87 | POLB (0.53) | DRD2HTR1ADRD3HTR2ADRD1 | |
| Hydrochloric Acid SCHEMBL26108377 | 0.87 | DRD2 (0.63) | DRD2HTR1ADRD3HTR2ADRD1 | |
| SCHEMBL9260064 | 0.84 | HTR1A (0.60) | DRD2HTR1ADRD3HTR2ADRD1 | |
| SCHEMBL15383635 | 0.83 | POLB (0.47) | DRD2HTR1ADRD3HTR2ADRD1 | |
| SCHEMBL9024932 | 0.83 | HTR1A (0.58) | DRD2HTR1ADRD3HTR2ADRD1 | |
| SCHEMBL7488440 | 0.83 | HTR1A (0.58) | DRD2HTR1ADRD3HTR2ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946031-A | Substituted aromatic phenol derivatives of KNa1.1 channel inhibitors | 北京大学 | 2024-04-30 | — | — | CN | claimed |
| US-20220098170-A1 | PROCESS FOR THE SYNTHESIS OF GEPIRONE | PROCOS S.P.A. (IT) | 2022-03-31 | — | — | US | claimed |
| WO-2020148621-A1 | PROCESS FOR THE SYNTHESIS OF GEPIRONE | PROCOS S.P.A. (IT) | 2020-07-23 | — | — | WO | claimed |
| CN-101880274-A | Method for preparing tandospirone and analogues of tandospirone | PKU INTERNAT HEALTHCARE GROUP SOUTHWEST PHARMACEUTICALS CO LTD | 2010-11-10 | — | — | CN | claimed |
| JP-59190990-A | — | — | None | — | — | JP | disclosed |
| CN-119438406-A | Detection method of related substances in tandospirone citrate | 四川科瑞德制药股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-117946031-A | Substituted aromatic phenol derivatives of KNa1.1 channel inhibitors | 北京大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-115611866-B | Preparation method of tandospirone citrate | 南京海纳医药科技股份有限公司 | 2024-04-23 | — | — | CN | disclosed |
| CN-117024414-A | Synthesis method of tandospirone citrate | 浙江九洲药业股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-115611866-A | Preparation method of tandospirone citrate | 南京海纳医药科技股份有限公司 | 2023-01-17 | — | — | CN | disclosed |
| US-20220098170-A1 | PROCESS FOR THE SYNTHESIS OF GEPIRONE | PROCOS S.P.A. (IT) | 2022-03-31 | — | — | US | disclosed |
| WO-2020148621-A1 | PROCESS FOR THE SYNTHESIS OF GEPIRONE | PROCOS S.P.A. (IT) | 2020-07-23 | — | — | WO | disclosed |
| US-4543355-A | Substituted succinimides, compositions and method of use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-09-24 | — | — | US | disclosed |
| US-4507303-A | Succinimide derivatives, compositions and method of use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-03-26 | — | — | US | disclosed |
| EP-0129128-A2 | 2-Pyrimidinyl-1-piperazine derivatives, process for their preparation and medicines containing them | Troponwerke GmbH & Co. KG (DE) | 1984-12-27 | — | — | EP | disclosed |
| JP-S59190990-A | CYCLIC IMIDE DERIVATIVE AND ITS ACID ADDITION SALT | SUMITOMO CHEM CO LTD | 1984-10-29 | — | — | JP | disclosed |
| EP-0109562-A1 | Succinimide derivatives and their production | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4423049-A | TRANQUILIZERS | MEAD JOHNSON & COMPANY (US) | 1983-12-27 | — | — | US | disclosed |
| EP-0082402-A2 | Succinimide derivates and process for preparation thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1983-06-29 | — | — | EP | disclosed |
| US-3976776-A | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones | MEAD JOHNSON & COMPANY (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220098170-A1 | PROCESS FOR THE SYNTHESIS OF GEPIRONE | GYPA, UGT2B7, UGT1A7 | DRD2 245/4885HTR1A 319/4885DRD3 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.